ÍøºìºÚÁÏ

Skip to main content

Carl J Pepine, MD

Cardiologist (Heart Specialist)

Photo of Carl J Pepine

Research at a glance

Top areas of exploration

  • Coronary Disease , 197 publications
  • Myocardial Ischemia , 186 publications
  • Coronary Artery Disease , 153 publications
  • Hypertension , 141 publications

Research activity

1,073 publications

53,734 citations

Why is this important?

Focus

My career has focused on improving our understanding of mechanisms underlying ischemic heart disease (IHD) and related adverse outcomes. I have conducted extensive investigations in coronary artery disease (CAD), hypertension, treatment resistant hypertension, vascular biology, and therapeutic applications related to vascular dysfunction. My work has centered on how IHD becomes manifest with and without large coronary artery obstructive disease (CAD). Much of this work is concentrated in women with known or suspect IHD. A major goal of clinical research is development of actionable information of sufficient power to alter medical care and improve patient health by information obtained through performance of clinical trials. To this end, I conceived and led the first randomized controlled international mega-trial of blood pressure control for patients with CAD (INVEST). My experience also includes being a principal investigator (PI) in multiple NHLBI-funded projects [Women’s Ischemia Syndrome Evaluation (WISE), WISE-CVD, WISE HFpEF, MayWEST, Asymptomatic Cardiac Ischemia Pilot (ACIP), Psychophysiologic Interventions of Myocardial Ischemia (PIMI), Bypass Angioplasty Revascularization Investigation 2-Diabetes Trial (BARI2D), etc.] and many other industry-sponsored studies. More recently I have been working in cardiovascular recovery and regeneration with cell based therapies as a PI in the NHLBI Cardiovascular Cell Therapy Network (CCTRN)- 1 and 2, as well as studies funded by the the cell and gene biomedical industry.

Active clinical trials

LIBREXIA-ACS

The purpose of this study is to evaluate if milvexian is at least as effective as apixaban for reducing the risk of the composite stroke and non-central nervous system (CNS) systemic embolism.

Investigator
Carl J Pepine
Status
Accepting Candidates
Ages
18 Years - N/A
Sexes
All
EVOLVE

The primary objective of this study is to evaluate the effectiveness of early treatment with evolocumab plus routine lipid management vs routine lipid management alone when administered in the acute setting to reduce myocardial infarction, ischemic…

Investigator
Carl J Pepine
Status
Accepting Candidates
Ages
18 Years - 99 Years
Sexes
All

My publications

1073 publications

2024

Impact of epicardial fat on coronary vascular function, cardiac morphology, and cardiac function in women with suspected INOCA.

European heart journal. Cardiovascular Imaging

•

2024

Initial Antihypertensive Prescribing in Relation to Blood Pressure Among Florida Medicaid and Medicare Recipients in the OneFlorida+ Research Consortium

Hypertension

2024

Intravenous administration of umbilical cord lining stem cells in left ventricular assist device recipients: Results of the uSTOP LVAD BLEED pilot study.

JHLT open

•

2024

Myocardial ischaemic syndromes: a new nomenclature to harmonize evolving international clinical practice guidelines.

European heart journal

•

2024

Myocardial Ischemic Syndromes: A New Nomenclature to Harmonize Evolving International Clinical Practice Guidelines

Circulation